Trial Profile
A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Aug 2021
Price :
$35
*
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms REMISSIO
- Sponsors Janssen-Cilag
- 01 May 2021 Results assessing impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate, published in the Comprehensive Psychiatry.
- 09 Oct 2018 Results assessing efficacy and tolerability of paliperidone 3-monthly formulation (PP3M) in schizophrenia, presented at the 31st Annual Congress of the European College of Neuropsychopharmacology.
- 09 Oct 2018 Results presented at the 31st Annual Congress of the European College of Neuropsychopharmacology